Erratum to clinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of \textit{EGFR}+ non-small cell lung cancer without the \textit{T790M} mutation

Xueyang Hu$^1$, Wenjun Chen$^2$, Xiaoqiu Li$^1$, Chenchen Zhao$^1$, Congjun Zhang$^1$, Fuxing Xiong$^1$, Hongyang Wu$^1$

$^1$Department of Medical Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei 230031, China; $^2$Phase I Clinical Center, Anhui Chest Hospital, Hefei 230022, China

$^*$These authors contributed equally to this work.

\textit{Correspondence to:} Hongyang Wu, MD, PhD. Department of Medical Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei 230031, China. Email: wuhoya1970@163.com.

doi: 10.21037/apm.2019.12.08

View this article at: http://dx.doi.org/10.21037/apm.2019.12.08

Erratum to: Ann Palliat Med 2019;8:525-31

\textbf{Clinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of EGFR+ non-small cell lung cancer without the T790M mutation}

In the November 2019 issue of \textit{Annals of Palliative Medicine}, the paper “Clinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of \textit{EGFR}+ non-small cell lung cancer without the \textit{T790M} mutation” (1) by Dr. Xueyang Hu \textit{et al.} was published with an error in the authorship.

The authors would like to correct and declare that the first two authors Dr. Xueyang Hu and Dr. Wenjun Chen contributed equally to this work, and being the co-first authors of this paper.

The authors regret the error and all inconveniences caused.

\textbf{References}
